Dr. David K. Henderson

Dr. Chloe Thio is a professor of medicine and an associate professor of molecular microbiology and immunology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include hepatitis, HIV/AIDS and infectious disease. Dr. Thio received her B.A. from the University of Pennsylvania. She earned her M.D. from the Yale University School of Medicine. She completed her residency at Hospital of the University of Pennsylvania and her fellowship in infectious diseases at Johns Hopkins. Her research interests include chronic hepatitis B and C and coinfection of viral hepatitis with HIV/AIDS. She has developed a program centered around virology and immunology translational work towards an HBV cure. Dr. Thio is a member of the American College of Physicians, the American Association for the Study of Liver Disease, the American Society of Clinical Investigation, HIVMA and the Infectious Diseases Society of America. Dr. Thio is rated as a Distinguished provider by MediFind in the treatment of Hepatitis B. Her top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, and HIV/AIDS.

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries. Dr. Sulkowski is rated as a Distinguished provider by MediFind in the treatment of Hepatitis B. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B.

Lydia Tang is an Infectious Disease provider in Baltimore, Maryland. Dr. Tang is rated as an Advanced provider by MediFind in the treatment of Hepatitis B. Her top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, and Liver Failure. Dr. Tang is currently accepting new patients.